Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes
A single center, prospective, one arm clinical study to assess the tolerance and effectiveness of total body irradiation and cladribine in adult patients diagnosed with AML( acute myeloid leukemia) and myelodysplastic syndromes.
Acute Myeloid Leukemia Myelodysplastic Syndromes
DRUG: Cladribine
The probability of progression-free survival in 24 month follow up, 24 month follow up
Frequency of adverse events, 24 month follow up|24-month overall survival probability, 24 month follow up|Disease recurrence probability., 24 month follow up|Mortality unrelated with disease recurrence, 24 month follow up|Likelihood of acute and chronic graft-versus-host disease, 24 month follow up|Time of neutrophil and platelet implantation, 24 month follow up
A single center, prospective, one arm clinical study to assess the tolerance and effectiveness of total body irradiation and cladribine in adult patients diagnosed with AML( acute myeloid leukemia) and myelodysplastic syndromes.